Apolipoprotein E4

"Apolipoprotein E4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A major and the second most common isoform of apolipoprotein E. In humans, Apo E4 differs from APOLIPOPROTEIN E3 at only one residue 112 (cysteine is replaced by arginine), and exhibits a lower resistance to denaturation and greater propensity to form folded intermediates. Apo E4 is a risk factor for ALZHEIMER DISEASE and CARDIOVASCULAR DISEASES.

Descriptor ID	D053327
MeSH Number(s)	D10.532.091.500.750 D12.776.070.400.500.750 D12.776.521.120.500.750
Concept/Terms	Apolipoprotein E4 Apolipoprotein E4 Apolipoprotein E-4 Apolipoprotein E 4 Apo E4 ApoE4 Apo E epsilon 4 Apo E-4 Apo E 4

Below are MeSH descriptors whose meaning is more general than "Apolipoprotein E4".

Chemicals and Drugs [D]
Lipids [D10]
Lipoproteins [D10.532]
Apolipoproteins [D10.532.091]
Apolipoproteins E [D10.532.091.500]
Apolipoprotein E4 [D10.532.091.500.750]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Apoproteins [D12.776.070]
Apolipoproteins [D12.776.070.400]
Apolipoproteins E [D12.776.070.400.500]
Apolipoprotein E4 [D12.776.070.400.500.750]
Lipoproteins [D12.776.521]
Apolipoproteins [D12.776.521.120]
Apolipoproteins E [D12.776.521.120.500]
Apolipoprotein E4 [D12.776.521.120.500.750]

Below are MeSH descriptors whose meaning is related to "Apolipoprotein E4".

Below are MeSH descriptors whose meaning is more specific than "Apolipoprotein E4".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Apolipoprotein E4" by people in this website by year, and whether "Apolipoprotein E4" was a major or minor topic of these publications.

Bar chart showing 40 publications over 19 distinct years, with a maximum of 4 publications in 2009 and 2011 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	1	1
2007	0	1	1
2009	4	0	4
2010	1	1	2
2011	3	1	4
2012	0	1	1
2013	1	0	1
2014	1	2	3
2015	0	1	1
2016	2	0	2
2017	0	2	2
2018	1	0	1
2019	0	1	1
2020	1	3	4
2021	2	1	3
2022	0	2	2
2023	1	2	3
2024	1	1	2
2025	1	1	2

Below are the most recent publications written about "Apolipoprotein E4" by people in Profiles.

Pappas I, Lohman T, Dutt S, Kapoor A, Engstrom AC, Alitin JPM, Barnes S, Chakhoyan A, Saca L, Gaggar R, Nourollahimoghadam E, Wang DJJ, Lai MHC, Joe EB, Ringman JM, Yassine HN, Schneider LS, Chui HC, Toga AW, Zlokovic BV, Nation DA. Cerebral hypoperfusion, brain structural integrity, and cognitive impairment in older APOE4 carriers. Geroscience. 2025 06; 47(3):4973-4986.

View in: PubMed
Wang B, Chibnik LB, Choi SH, Blacker D, DeStefano AL, Lin H. Association of genetic risk of Alzheimer's disease and cognitive function in two European populations. Sci Rep. 2025 Feb 21; 15(1):6410.

View in: PubMed
Kapoor A, Dutt S, Alitin JPM, Sible IJ, Marshall A, Shenasa F, Engstrom AC, Gaubert A, Shao X, Bradford DR, Rodgers K, Mather M, Wang DJJ, Nation DA. Older adults with reduced cerebrovascular reactivity exhibit high white matter hyperintensity burden. Neurobiol Aging. 2024 07; 139:5-10.

View in: PubMed
Ferguson CM, Hildebrand S, Godinho BMDC, Buchwald J, Echeverria D, Coles A, Grigorenko A, Vangjeli L, Sousa J, McHugh N, Hassler M, Santarelli F, Heneka MT, Rogaev E, Khvorova A. Silencing Apoe with divalent-siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's disease. Alzheimers Dement. 2024 04; 20(4):2632-2652.

View in: PubMed
Groechel RC, Tripodis Y, Alosco ML, Mez J, Qiao Qiu W, Goldstein L, Budson AE, Kowall NW, Shaw LM, Weiner M, Jack CR, Killiany RJ. Biomarkers of Alzheimer's disease in Black and/or African American Alzheimer's Disease Neuroimaging Initiative (ADNI) participants. Neurobiol Aging. 2023 11; 131:144-152.

View in: PubMed
Deming Y, Vasiljevic E, Morrow A, Miao J, Van Hulle C, Jonaitis E, Ma Y, Whitenack V, Kollmorgen G, Wild N, Suridjan I, Shaw LM, Asthana S, Carlsson CM, Johnson SC, Zetterberg H, Blennow K, Bendlin BB, Lu Q, Engelman CD. Neuropathology-based APOE genetic risk score better quantifies Alzheimer's risk. Alzheimers Dement. 2023 08; 19(8):3406-3416.

View in: PubMed
Heneka MT. ApoE4 makes microglia trem2bling. Neuron. 2023 01 18; 111(2):142-144.

View in: PubMed
Hajjar I, Yang Z, Okafor M, Liu C, Waligorska T, Goldstein FC, Shaw LM. Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors. JAMA Netw Open. 2022 10 03; 5(10):e2235068.

View in: PubMed
Gustavson DE, Reynolds CA, Hohman TJ, Jefferson AL, Elman JA, Panizzon MS, Neale MC, Logue MW, Lyons MJ, Franz CE, Kremen WS. Alzheimer's Disease Polygenic Scores Predict Changes in Episodic Memory and Executive Function Across 12 Years in Late Middle Age. J Int Neuropsychol Soc. 2023 Feb; 29(2):136-147.

View in: PubMed
Janssen O, Jansen WJ, Vos SJB, Boada M, Parnetti L, Gabryelewicz T, Fladby T, Molinuevo JL, Villeneuve S, Hort J, Epelbaum S, Lleó A, Engelborghs S, van der Flier WM, Landau S, Popp J, Wallin A, Scheltens P, Rikkert MO, Snyder PJ, Rowe C, Chételat G, Ruíz A, Marquié M, Chipi E, Wolfsgruber S, Heneka M, Boecker H, Peters O, Jarholm J, Rami L, Tort-Merino A, Binette AP, Poirier J, Rosa-Neto P, Cerman J, Dubois B, Teichmann M, Alcolea D, Fortea J, Sánchez-Saudinós MB, Ebenau J, Pocnet C, Eckerström M, Thompson L, Villemagne V, Buckley R, Burnham S, Delarue M, Freund-Levi Y, Wallin ÅK, Ramakers I, Tsolaki M, Soininen H, Hampel H, Spiru L, Tijms B, Ossenkoppele R, Verhey FRJ, Jessen F, Visser PJ. Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimers Dement. 2022 10; 18(10):1832-1845.

View in: PubMed

People

Explore

Similar Concepts

Top Journals